Opendata, web and dolomites

PMLingAML SIGNED

Using PML nuclear body biology to identify potential AML treatment targets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMLingAML project word cloud

Explore the words cloud of the PMLingAML project. It provides you a very rough idea of what is the project "PMLingAML" about.

formerly    clinical    pmlingaml    therapeutic    roles    previously    dynamics    sumoylome    nbs    elucidating    npm1    flt3itd    excision    mass    isolated    drug    patient    progenitor    majority    identification    dna    c65a    lsk    alpha    samples    murine    repair    respective    mouse    vast    dactinomycin    trial    npm1c    model    status    cells    subset    poor    share    successful    mechanisms    disrupted    carry    pathogenesis    pmlc62a    leukemic    combination    marrows    hematopoietic    models    mimics    decipher    inter    nuclear    leukemia    treatment    function    outcome    aml    analysing    cured    stem    therapy    understanding    leukemogenesis    scrutinised    promyelocytic    pml    resolution    patients    imaging    myeloid    acute    mutation    initiation    lethal    oncoprotein    disruption    body    healthy    functions    bone    nb    rar    spectrometry    relationship    localisation    shown    underlying    promyelocytes    incl    strategies    ber    assuredly    mutated    biology    cellular    base    knock    apl    damage   

Project "PMLingAML" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 184˙707 €
 EC max contribution 184˙707 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 184˙707.00

Map

 Project objective

Understanding the initiation and development of acute myeloid leukemia (AML) represents an important challenge which may lead to the identification of new therapeutic strategies. Acute promyelocytic leukemia (APL) was formerly the most lethal subset of AML; however, today the vast majority of APL patients can be cured by combination therapy. Therefore, fully understanding the mechanisms underlying successful treatment, by analysing the biology of APL pathogenesis will assuredly improve the management of AML subsets associated with a poor outcome, such as NPM1-mutated AML. Using a novel knock-in mouse model, PmlC62A/C65A, which mimics Pml nuclear body (NB) disruption induced by the main oncoprotein PML-RARα in APL, we have previously shown that Pml NBs are essential in APL pathogenesis and treatment response. Our project “PMLingAML” aims to carry on elucidating the impact of Pml NB disruption in APL, and then to apply this knowledge in other AML subsets. To this end, a mass spectrometry analysis will be conducted on both hematopoietic stem and progenitor (LSK) cells and promyelocytes isolated from healthy and leukemic murine bone marrows, to decipher the consequences of Pml NB disruption on the SUMOylome. Next, since PML NBs and NPM1 share common cellular functions and characteristics, we will analyse the inter-relationship between them; their localisation and dynamics will be assessed according to their respective status (disruption, mutation, knock-out), for example by high resolution imaging, both in various healthy and leukemic mouse models (incl NPM1c and NPM1c/FLT3ITD), and in patient samples. Their respective roles in response to a drug under clinical trial, Dactinomycin, will also be scrutinised. Finally, as DNA damage repair is an important function disrupted during leukemogenesis, the roles of Pml NBs and Npm1 will be assessed together with their inter-relationship, with particular focus on the base excision repair (BER) pathway.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMLINGAML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMLINGAML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

InBPSOC (2020)

Increases biomass production and soil organic carbon stocks with innovative cropping systems under climate change

Read More